Early central nervous system complications after reduced-intensity stem cell transplantation

Patchell, 1985, Neurologic complications of bone marrow transplantation, Neurology, 35, 300, 10.1212/WNL.35.3.300 Graus, 1996, Neurologic complications of autologous and allogeneic bone marrow transplantation in patients with leukemia, Neurology, 46, 1004, 10.1212/WNL.46.4.1004 Wiznitzer, 1984, Neurological complications of bone marrow transplantation in childhood, Ann Neurol., 16, 569, 10.1002/ana.410160507 Mohrmann, 1990, Neuropathologic findings after bone marrow transplantation, Hum Pathol., 21, 630, 10.1016/S0046-8177(96)90010-6 Gallardo, 1996, Neurologic complications after allogeneic bone marrow transplantation, Bone Marrow Transplant., 18, 1135 de Brabander, 2000, Increased incidence of neurological complications in patients receiving an allogenic bone marrow transplantation from alternative donors, J Neurol Neurosurg Psychiatry, 68, 36, 10.1136/jnnp.68.1.36 Sostak, 2003, Prospective evaluation of neurological complications after allogeneic bone marrow transplantation, Neurology, 60, 842, 10.1212/01.WNL.0000046522.38465.79 Bleggi-Torres, 2000, Neuropathological findings after bone marrow transplantation, Bone Marrow Transplant., 25, 301, 10.1038/sj.bmt.1702140 Openshaw, 1995, Immune-mediated myelopathy after allogeneic marrow transplantation, Bone Marrow Transplant., 15, 633 Rouah, 1988, Graft-versus-host disease in the central nervous system. A real entity?, Am J Clin Pathol., 89, 543, 10.1093/ajcp/89.4.543 Slavin, 1998, Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases, Blood, 91, 756, 10.1182/blood.V91.3.756 Giralt, 1997, Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy, Blood, 89, 4531, 10.1182/blood.V89.12.4531 Saito, 2002, Therapeutic potential of a reduced-intensity preparative regimen for allogeneic transplantation with cladribine, busulfan, and antithymocyte globulin against advanced/refractory acute leukemia/lymphoma, Clin Cancer Res., 8, 1014 McSweeney, 2001, Hematopoietic cell transplantation in older patients with hematologic malignancies, Blood, 97, 3390, 10.1182/blood.V97.11.3390 Xun, 1999, Successful nonmyeloablative allogeneic hematopoietic stem cell transplant in an acute leukemia patient with chemotherapy-induced marrow aplasia and progressive pulmonary aspergillosis, Blood, 94, 3273, 10.1182/blood.V94.9.3273 Mielcarek, 2003, Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation, Blood, 102, 756, 10.1182/blood-2002-08-2628 Fukuda, 2003, Risks and outcomes of invasive fungal infections in recipients of allogeneic hematopoietic stem cell transplants after nonmyeloablative conditioning, Blood, 102, 827, 10.1182/blood-2003-02-0456 Childs, 2000, Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation, N Engl J Med., 343, 750, 10.1056/NEJM200009143431101 Bornhauser, 2000, Dose-reduced conditioning for allogeneic blood stem cell transplantation, Bone Marrow Transplant., 26, 119, 10.1038/sj.bmt.1702500 Giralt, 2001, Melphalan and purine analog-containing preparative regimens, Blood, 97, 631, 10.1182/blood.V97.3.631 De La Camara, 1991, High dose busulfan and seizures, Bone Marrow Transplant., 7, 363 Bearman, 1988, Regimen-related toxicity in patients undergoing bone marrow transplantation, J Clin Oncol., 6, 1562, 10.1200/JCO.1988.6.10.1562 Provenzale, 1996, Reversible leukoencephalopathy associated with graft-versus-host disease, AJNR Am J Neuroradiol., 17, 1290 Bechstein, 2000, Neurotoxicity of calcineurin inhibitors, Transpl Int., 13, 313, 10.1111/j.1432-2277.2000.tb01004.x Gijtenbeek, 1999, Cyclosporine neurotoxicity, J Neurol., 246, 339, 10.1007/s004150050360 Von Hoff, 1990, Phase I clinical trials with fludarabine phosphate, Semin Oncol., 17, 33 Chun, 1986, Central nervous system toxicity of fludarabine phosphate, Cancer Treat Rep., 70, 1225 Spriggs, 1986, Fludarabine phosphate (NSC 312878) infusions for the treatment of acute leukemia, Cancer Res., 46, 5953 Warrell, 1986, Phase I and II study of fludarabine phosphate in leukemia, J Clin Oncol., 4, 74, 10.1200/JCO.1986.4.1.74 Merkel, 1986, Central nervous system toxicity with fludarabine, Cancer Treat Rep., 70, 1449 Vidarsson, 2002, Progressive multifocal leukoencephalopathy after fludarabine therapy for low-grade lymphoproliferative disease, Am J Hematol., 70, 51, 10.1002/ajh.10085 Cohen, 1993, Reversible neurologic toxicity in patients treated with standard-dose fludarabine phosphate for mycosis fungoides and chronic lymphocytic leukemia, Ann Intern Med., 118, 114, 10.7326/0003-4819-118-2-199301150-00007 Wong, 2003, Tacrolimus-associated posterior reversible encephalopathy syndrome after allogeneic haematopoietic stem cell transplantation, Br J Haematol., 122, 128, 10.1046/j.1365-2141.2003.04447.x Miyakoshi, 2004, Successful engraftment following reduced-intensity umbilical cord blood transplantation (RI-UCBT) for adult patients with advanced hematologic diseases, Clin Cancer Res., 10, 3586, 10.1158/1078-0432.CCR-03-0754 Gordon, 2000, Central nervous system dysfunction as the first manifestation of multiple organ dysfunction syndrome in stem cell transplant patients, Bone Marrow Transplant., 25, 79, 10.1038/sj.bmt.1702082 Laughlin, 2001, Hematopoietic engraftment and survival in adult recipients of umbilical-cord blood from unrelated donors, N Engl J Med., 344, 1815, 10.1056/NEJM200106143442402